NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors

NCT05382377 | Recruiting Early Phase 1

• 1 other identifier: KD-025-XJM
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of advanced NKG2DL+ solid tumors.

Conditions

CRC; Solid Tumor

Keywords

NKG2D

Outcome Measures

Primary Outcomes (3)

• treatment-emergent adverse events(TEAEs)

  An adverse event is any undesirable experience associated with the use of a medical product in a patient

  3 months after single infusion

• Dose-limiting toxicity (DLT) rate

  A drug-related toxicity during treatment with the drug, the severity of which is clinically unacceptable, limiting the further escalation of drug dose.

  3 months after single infusion

• CAR positive T cells in patients

  The time of CAR-T cell reach the peak and turn back to baseline

  6 months after single infusion

Secondary Outcomes (3)

• Objective response rate(ORR)

  1 month, 2 month, 3 month, 6 month, 1 year after cell infusion

• Progression free survival(PFS)

  1 month, 2 month, 3 month, 6 month, 1 year after cell infusion

• Complete remission (CR)

  1 month, 2 month, 3 month, 6 month, 1 year after cell infusion

Study Arms (1)

KD-025 cell infusion

EXPERIMENTAL

Each subject will receive KD-025 cell infusion

Biological: KD-025

Interventions

KD-025 BIOLOGICAL

Autologous genetically modified anti-NKG2DLs CAR transduced T cells

KD-025 cell infusion

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients diagnosed as advanced solid tumors histopathologically or cytologically, such as ovarian, cholangiocarcinoma, and colorectal cancer.
• Patients fail standard treatment , or cannot tolerate standard treatment, or there is no standard treatment, the standard treatment recommendations refer to the latest version of the guidelines of the national comprehensive cancer network (NCCN) or the guidelines of the Chinese society of Clinical Oncology (CSCO);
• Age 18-70 years;
• ECOG score 0-1;
• Expected survival ≥ 3 months;
• Patients must meet coagulation parameters and have adequate peripheral venous access for apheresis, and must also have enough PBMC to manufacture CAR T cells;
• NKG2DL (according to the positive comprehensive score of 0-12 points, positive SCORE of NKG2DL ≥2) positive confirmed by Immunohistochemistry. Biopsy tissue must be no more than 1 year, if not, must obtain new tissue material from a recent surgical or diagnostic biopsy;
• Eligible organ and bone marrow functions defined as follows:1) Absolute neutrophil count ≥1.5×10\^9/L, lymphocyte count ≥0.5×10\^9/L, platelet count ≥90×10\^9/L, hemoglobin ≥90g/L (no blood transfusion or Erythropoietin within 7 days); 2) Total bilirubin ≤2ULN; Serum alanine amino transferase (ALT) or aspartate aminotransferase (AST)≤2.5ULN (≤2.5 times with liver metastasis); 3) Creatinine ≤1.5ULN or eGFR≥ 60mL /min/1.73m\^2 \[eGFR=186×(age)-0.203×SCr-1.154(mg/dl), eGFR timing in women was 0.742\]; 4) International normalized ratio (INR) or prothrombin time (PT) ≤1.5ULN; 5) Lung function: ≤ grade 1 dyspnea (according to NCI-CTCAE V5.0), SaO2≥91%; 6) Cardiac function: Cardiac ejection fraction (LVEF) detected by echocardiography or MUGA ≥50% 1 month before enrollment.
• Patients must have measurable lesions as defined by RECIST 1.1;
• Patients fully understand the test and voluntarily sign the informed consent;
• Patient agree to use approved contraceptive methods (e.g., birth control pills, barrier devices, iuds, contraindicated drugs) during the study and for at least 12 months after last cell infusion, until no CAR-T cells were detected by two consecutive PCR tests.

You may not qualify if:

• Patients had received any gene therapy (including CAR-T cell therapy) or any T cell therapy, Active bacteria or viral or fungal infection and not controlled after anti-infective treatment (positive blood test 72 hours before infusion), Syphilis, Human immunodeficiency virus (HIV), Active hepatitis B (HBV DNA≥500IU/ml) or hepatitis c (anti-HCV positive and HCV RNA higher than the detection limit of analysis method);
• Patients have an autoimmune disease or organ transplant, require chronic systemic steroid therapy or any other form of immunosuppressive drugs;
• A history of serious heart or lung disease, including uncontrolled hypertension medication, and any condition that occurred within the past 6 months: congestive heart failure (New York Heart Association functional classification ≥3), cardiac angioplasty and stents, myocardial infarction, unstable angina, or other clinically severe heart disease;
• Detected clinically relevant central nervous system (CNS) metastases and/or pathologies, such as seizures, cerebral ischemia/bleeding, dementia, cerebellar diseases or autoimmune diseases affecting the CNS;
• The Patients' history or existing evidence of any condition such as neuroticism, psychosis, immunology, metabolism, and infectious disease, in any treatment, or laboratory abnormalities may confuse the outcome of the study, interfere with the Patients' participation during the study, or not participate in the Patients' best interests with investigator treatment;
• The Patients have a history of hematologic malignancy or concurrent history of other malignant primary solid tumors, except for: 1) Patients with cervical or breast cancer in situ who have no evidence of disease for more than 3 years after radical treatment; 2) Patients who have successfully received definite resection of tumor in situ and have no evidence of disease for ≥5 years;
• Received chemotherapy, radiation, small molecule, biologic cancer therapy, immunotherapy, or other experimental drugs within 4 weeks prior to study initiation,
• Pregnant or lactating women;
• The investigator considers the Patients have or with current historical evidence of any condition, therapy, or laboratory anomaly that may confound the results of the study, interfere with the Patients' participation in the fulltime study and the requirements of the cooperative trial, not controlled medical, psychological, family, social, or geographic conditions, or not participate.

Sponsors & Collaborators

• jianming xu: lead
• KAEDI: collaborator

Study Sites (1)

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

RECRUITING

MeSH Terms

Interventions

KD025

Central Study Contacts

Jianming Xu, M.D

CONTACT

13910866712; jianmingxu2014@163.com

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Leading Site Principal Investigator

Study Record Dates

• First Submitted: May 16, 2022
• First Posted: May 19, 2022
• Study Start: May 17, 2022
• Primary Completion: May 17, 2024
• Study Completion (Estimated): May 17, 2026
• Last Updated: May 19, 2022

Record last verified: 2022-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)